The city of Boston, Massachusetts, currently has 141 active clinical trials seeking participants for Breast Cancer research studies.
TRUDI: TDXD+Durva in HER2+/low IBC
NCT05795101
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Register for Updates
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT05593094
Recruiting
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Dana-Farber Cancer Insitute, Boston, Massachusetts
Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Register for Updates
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT06488378
Recruiting
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Register for Updates
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT04368702
Recruiting
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Brigham & Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Register for Updates
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT05327452
Recruiting
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients. The names of the study interventions involved in this study are: * Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom. * Unsupervised aerobic and resistance exercise (UNSUP) - ho... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT02926729
Recruiting
This research is studying a new investigative imaging instrument called a nonlinear microscope (NLM). A nonlinear microscope can produce images similar to an ordinary pathologist's microscope, but without first processing tissue to make slides. This study will determine if a NLM can be used to evaluate tissue during lumpectomy surgery for breast cancer in order to reduce the probability that standard pathologic examination of the specimen after the end of the operation will find close or positiv... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Testing Conversation Aid in Practice
NCT06011434
Recruiting
The goal of this research study is to develop and test a website to help primary care providers (PCPs) discuss the pros and cons of mammography with women aged 75 and older and to help participants make decisions about mammography.
Gender:
FEMALE
Ages:
Between 75 years and 89 years
Trial Updated:
05/07/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT03285412
Recruiting
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230
Recruiting
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT02290834
Recruiting
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Register for Updates